Trials / Completed
CompletedNCT00445458
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn whether it is safe and effective to administer HKI-272 (neratinib) in combination with paclitaxel in patients with breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HKI-272 | |
| DRUG | Paclitaxel |
Timeline
- Start date
- 2007-09-11
- Primary completion
- 2011-05-01
- Completion
- 2018-02-07
- First posted
- 2007-03-09
- Last updated
- 2018-07-26
- Results posted
- 2018-05-09
Locations
32 sites across 9 countries: United States, Belgium, Canada, China, Hong Kong, India, Poland, South Korea, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00445458. Inclusion in this directory is not an endorsement.